These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
49. Molecular complexities underlying the vascular complications of diabetes mellitus - A comprehensive review. Paul S; Ali A; Katare R J Diabetes Complications; 2020 Aug; 34(8):107613. PubMed ID: 32505477 [TBL] [Abstract][Full Text] [Related]
50. Epigenetics, microRNA and Metabolic Syndrome: A Comprehensive Review. Ramzan F; Vickers MH; Mithen RF Int J Mol Sci; 2021 May; 22(9):. PubMed ID: 34068765 [TBL] [Abstract][Full Text] [Related]
51. Role of histone modification and DNA methylation in signaling pathways involved in diabetic retinopathy. Shafabakhsh R; Aghadavod E; Ghayour-Mobarhan M; Ferns G; Asemi Z J Cell Physiol; 2019 Jun; 234(6):7839-7846. PubMed ID: 30515789 [TBL] [Abstract][Full Text] [Related]
52. Epigenetic modifications of Nrf2-mediated glutamate-cysteine ligase: implications for the development of diabetic retinopathy and the metabolic memory phenomenon associated with its continued progression. Mishra M; Zhong Q; Kowluru RA Free Radic Biol Med; 2014 Oct; 75():129-39. PubMed ID: 25016074 [TBL] [Abstract][Full Text] [Related]
54. Epigenetic signatures and vascular risk in type 2 diabetes: a clinical perspective. Paneni F; Costantino S; Volpe M; Lüscher TF; Cosentino F Atherosclerosis; 2013 Oct; 230(2):191-7. PubMed ID: 24075743 [TBL] [Abstract][Full Text] [Related]
55. Epigenetic modifications and metabolic memory in diabetic retinopathy: beyond the surface. Liu DD; Zhang CY; Zhang JT; Gu LM; Xu GT; Zhang JF Neural Regen Res; 2023 Jul; 18(7):1441-1449. PubMed ID: 36571340 [TBL] [Abstract][Full Text] [Related]
56. Epigenetic modifications and potential new treatment targets in diabetic retinopathy. Perrone L; Matrone C; Singh LP J Ophthalmol; 2014; 2014():789120. PubMed ID: 25165577 [TBL] [Abstract][Full Text] [Related]
57. Diabetes-induced epigenetic signature in vascular cells. Mitić T; Emanueli C Endocr Metab Immune Disord Drug Targets; 2012 Jun; 12(2):107-17. PubMed ID: 22236027 [TBL] [Abstract][Full Text] [Related]
58. Emerging Role of Long Non-Coding RNAs in Diabetic Vascular Complications. Tanwar VS; Reddy MA; Natarajan R Front Endocrinol (Lausanne); 2021; 12():665811. PubMed ID: 34234740 [TBL] [Abstract][Full Text] [Related]
59. Metabolic memory: mechanisms and implications for diabetic vasculopathies. Zhang E; Wu Y Sci China Life Sci; 2014 Aug; 57(8):845-51. PubMed ID: 25104458 [TBL] [Abstract][Full Text] [Related]
60. The Role of Fibroblast Growth Factor 21 in Diabetic Cardiovascular Complications and Related Epigenetic Mechanisms. Xiao M; Tang Y; Wang S; Wang J; Wang J; Guo Y; Zhang J; Gu J Front Endocrinol (Lausanne); 2021; 12():598008. PubMed ID: 34349728 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]